Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Are you Dr. Shelburne?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Samuel Shelburne, MD is an infectious disease specialist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.
Education & Training
Baylor College of MedicineFellowship, Infectious Disease, 2002 - 2005- Baylor College of MedicineResidency, Internal Medicine, 1998 - 2002
University of Texas Medical Branch School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
- Join now to see all
Publications & Presentations
PubMed
- Infections Due to Corynebacterium kroppenstedtii With Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup, and Treatment.Qiong Gan, Yang Ding, Yun Wu, Yu Zhang, Qing H Meng
Archives of Pathology & Laboratory Medicine. 2025-01-13 - Rapid whole genome characterization of antimicrobial-resistant pathogens using long-read sequencing to identify potential healthcare transmission.Chin-Ting Wu, William C Shropshire, Micah M Bhatti, Sherry Cantu, Israel K Glover
Infection Control and Hospital Epidemiology. 2024-12-27 - Comprehensive Assessment of Initial Adaptation of ESBL Positive ST131 Escherichia coli to Carbapenem Exposure.William C Shropshire, Xinhao Song, Jordan Bremer, Seokju Seo, Susana Rodriguez
The Journal of Infectious Diseases. 2024-11-27
Press Mentions
Editorial BoardJune 24th, 2020- Developing Novel Therapies Targeting the Tumor Microenvironment of Aggressive Breast CancerApril 3rd, 2025
Grant Support
- Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)METHODIST HOSPITAL RESEARCH INSTITUTE2020–2026
- Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)METHODIST HOSPITAL RESEARCH INSTITUTE2020–2026
- Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)METHODIST HOSPITAL RESEARCH INSTITUTE2020–2026
- Delineation of mechanisms underlying response regulator activation in group A StreptococcusUNIVERSITY OF TX MD ANDERSON CAN CTR2024–2025
- Delineation of mechanisms underlying response regulator activation in group A StreptococcusUNIVERSITY OF TX MD ANDERSON CAN CTR2024–2025
- Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcusUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2025
